Giménez Sanz, Noemí

Institutions of which they are part

Infection and immunity in pediatric patients

Vall Hebron Institut de Recerca

Giménez Sanz, Noemí

Institutions of which they are part

Infection and immunity in pediatric patients

Vall Hebron Institut de Recerca

Projects

RBDCOV: RBD Dimer recombinant protein vaccine against SARSCoV2

IP: Pere Soler Palacín
Collaborators: Miriam Gonzalez Amores, Tamara Del Rio Higueras, Ariadna Martín Balcells, Amaia Latasa Arrazubi, Noemí Giménez Sanz, Olga Sánchez- Maroto Carrizo, Maria Soraya Badia Ventura
Funding agency: EUROPEAN COMMISSION
Funding: 475000
Reference: RBDCOV_HE-HLTH-CORONA2021
Duration: 01/12/2021 - 31/05/2024

Related news

Significant advancements and a fifteen-month extension for the RBDCOV Project

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

A study describes a genetic mechanism related to a type of immunodeficiency in women

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.